A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at
Randomization and every four weeks from Week 4 through Week 52 and through End of Study
period. The study includes a post-dosing study visit that will occur 4 weeks after the last
dose of study drug. This visit represents the End-of-Study Visit (Week 56 Visit). Three
hundred thirty-seven subjects will be enrolled into five treatment arms and there will be an
equal distribution of males and females in each treatment arm. Subjects will be stratified by
gender, fibrosis stage, and diabetes status.